Literature DB >> 10482089

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.

A G Konstas1, A C Maltezos, S Gandi, A C Hudgins, W C Stewart.   

Abstract

PURPOSE: To compare the 24-hour diurnal ocular hypotensive efficacy of two dosing regimens of latanoprost, once daily (8 AM or 10 PM), vs timolol maleate, twice daily.
METHODS: We measured six diurnal intraocular pressure curves (6 AM, 10 AM, 2 PM, 6 PM, 10 PM, and 2 AM) in one randomly selected eye of 34 Greek patients newly diagnosed with primary open-angle glaucoma. The first diurnal curve was an untreated baseline. Patients began taking timolol 0.5%, twice daily, for 2 months. Patients were randomly assigned to latanoprost 0.005% given at 8 AM or 10 PM for 1 month and then changed to the other dosing regimen for 1 month. A diurnal curve was performed after each dosing period.
RESULTS: The baseline diurnal pressure for all 34 subjects was 23.1 +/- 3.7 mm Hg. The average intraocular pressures at 6 AM for patients who were given latanoprost in the evening (17.9 +/- 2.9 mm Hg) was statistically lower than that in patients given timolol solution (20.1 +/- 2.5 mm Hg, P = .003); however, patients who were given timolol demonstrated a similar diurnal intraocular pressure (19.1 +/- 2.8 mm Hg) to both morning (18.8 +/- 3.7 mm Hg) and evening doses (18.8 +/- 3.6 mm Hg) of latanoprost (P =.329). When the two latanoprost dosages were compared directly, evening administration provided a statistically lower intraocular pressure at 10 AM (P = .0001) and morning administration at 10 PM (P = .0001). This study had an 80% power to exclude a 1.2-mm Hg difference between groups.
CONCLUSIONS: This study indicates that in a small population, both latanoprost and timolol are effective in lowering intraocular pressure throughout a 24-hour period; however, latanoprost is most effective in the 12-hour to 24-hour period after administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482089     DOI: 10.1016/s0002-9394(99)00073-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  19 in total

1.  A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.

Authors:  J García-Sánchez; J-F Rouland; D Spiegel; B Pajic; I Cunliffe; C Traverso; J Landry
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.

Authors:  Chandrasekar Durairaj
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

3.  Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.

Authors:  W Y Zhang; A L Po; H S Dua; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

4.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

5.  Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.

Authors:  Chandrasekar Durairaj; Jie Shen; Madhu Cherukury
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

6.  The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2008

7.  A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.

Authors:  M Diestelhorst; L-I Larsson
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

8.  Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany.

Authors:  Ulrich Thelen; Dietmar Schnober; Sonja Schölzel; Michael S Kristoffersen; Lindsay A Nelson; Jeanette A Stewart; William C Stewart
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

Review 9.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients.

Authors:  Makoto Ishikawa; Takeshi Yoshitomi
Journal:  Clin Ophthalmol       Date:  2009-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.